Literature DB >> 2961881

Antagonism by naltrexone of the hypotension and bradycardia induced by alpha-methyldopa in conscious normotensive rats.

P L van Giersbergen1, W de Jong.   

Abstract

The possible role of the endogenous opioid system in the central hypotensive mechanism of action of alpha-methyldopa was investigated. Conscious normotensive Wistar rats were used in this study and all treatments were given intracisternally. Pretreatment with the opiate receptor antagonist naltrexone resulted in a parallel shift to the right of the dose-response curve for alpha-methyldopa, both for blood pressure and heart rate. In addition, when increasing doses of naltrexone and a constant dose of alpha-methyldopa were used the opiate receptor antagonist inhibited dose-dependently alpha-methyldopa-induced hypotension but not the bradycardia. Administration of naltrexone after the injection of alpha-methyldopa failed to reverse or inhibit alpha-methyldopa-induced hypotension, indicating that the interaction between alpha-methyldopa and the endogenous opioid system occurs at the start of the action of alpha-methyldopa. An antiserum against endorphins also inhibited the fall in blood pressure after alpha-methyldopa. These findings indicate that stimulation of opiate receptors, probably by an endorphin, is involved in the mechanism of action of alpha-methyldopa and that this stimulation seems to occur at the start of the action of alpha-methyldopa.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2961881

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  2 in total

1.  Alpha-methyldopa induces a naltrexone-insensitive antinociception and hypomotility in rats.

Authors:  P L van Giersbergen; E van Duinkerken; C G Sweep; V M Wiegant; J M van Ree; W de Jong
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

2.  Neuroinflammatory reactions in experimental gastric ulcer: target for mucosal protection.

Authors:  K Gyires
Journal:  Inflammopharmacology       Date:  1997       Impact factor: 4.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.